Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy.
Sinha S, Boysen JC, Chaffee KG, Kabat BF, Slager SL, Parikh SA, Secreto CR, Call T, Shanafelt TD, Leis JF, Warner SL, Bearss DJ, Ghosh AK, Kay NE.
Sinha S, et al. Among authors: kay ne.
Oncotarget. 2018 Dec 14;9(98):37173-37184. doi: 10.18632/oncotarget.26444. eCollection 2018 Dec 14.
Oncotarget. 2018.
PMID: 30647852
Free PMC article.